Key result
Heart transplantation is the optimal treatment for selected patients with end-stage heart failure, with 1-year survival around 90% and median survival exceeding 10 years.
This review summarizes the current state of heart transplantation, highlighting changing patient demographics, advances in immunosuppression, and the management of allosensitization.
Answers are grounded in this paper and cite their sources.
Supports heart transplantation in selected end-stage HF; leaves open refinements in immunosuppression and allosensitization amid shifting demographics.
Since the first heart transplant, refinement of donor and recipient selection methods, better donor heart management, and advances in immunosuppression have significantly improved survival. In this first of two articles, a perspective of the current realities of cardiac transplantation is shown, as well as the challenges to sustain services worldwide, and some of the new developments, both presently available and just beyond the horizon. Topics that will be covered in this first part include the donor and recipient demographics, as well as recent advances in transplantation immunology, allograft vasculopathy, and immune tolerance.
No takes yet. Share an insight, caveat, or question.
Babar Chaudhri (2014) conducted a review in End-stage heart failure. Heart transplantation was evaluated. Heart transplantation is the optimal treatment for selected patients with end-stage heart failure, with 1-year survival around 90% and median survival exceeding 10 years.
Synapse has enriched 10 related papers. Consider them for comparative context: